Vitamin D receptor polymorphisms in patients with cutaneous melanoma
β Scribed by Irene Orlow; Pampa Roy; Anne S. Reiner; Sarah Yoo; Himali Patel; Susan Paine; Bruce K. Armstrong; Anne Kricker; Loraine D. Marrett; Robert C. Millikan; Nancy E. Thomas; Stephen B. Gruber; Hoda Anton-Culver; Stefano Rosso; Richard P. Gallagher; Terence Dwyer; Peter A. Kanetsky; Klaus Busam; Lynn From; Colin B. Begg; Marianne Berwick; for the GEM Study Group
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- French
- Weight
- 474 KB
- Volume
- 130
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The vitamin D receptor (VDR) gene has been associated with cancer risk, but only a few polymorphisms have been studied in relation to melanoma risk and the results have been inconsistent. We examined 38 VDR gene single nucleotide polymorphisms (SNPs) in a large international multicenter populationβbased caseβcontrol study of melanoma. Buccal DNAs were obtained from 1,207 people with incident multiple primary melanoma and 2,469 with incident single primary melanoma. SNPs with known or suspected impact on VDR activity, haplotype tagging SNPs with β₯10% minor allele frequency in Caucasians, and SNPs reported as significant in other association studies were examined. Logistic regression was used to calculate the relative risks conferred by the individual SNP. Eight of 38 SNPs in the promoter, coding, and 3β² gene regions were individually significantly associated with multiple primary melanoma after adjusting for covariates. The estimated increase in risk for individuals who were homozygous for the minor allele ranged from 25 to 33% for six polymorphisms: rs10875712 (odds ratios [OR] 1.28; 95% confidence interval (CI), 1.01β1.62), rs4760674 (OR 1.33; 95% CI, 1.06β1.67), rs7139166 (OR 1.26; 95%CI, 1.02β1.56), rs4516035 (OR 1.25; 95%CI, 1.01β1.55), rs11168287 (OR 1.27; 95%CI, 1.03β1.57) and rs1544410 (OR 1.30; 95%CI, 1.04β1.63); for two polymorphisms, homozygous carriers had a decreased risk: rs7305032 (OR 0.81; 95%CI 0.65β1.02) and rs7965281 (OR, 0.78; 95%CI, 0.62β0.99). We recognize the potential false positive findings because of multiple comparisons; however, the eight significant SNPs in our study outnumbered the two significant tests expected to occur by chance. The VDR may play a role in melanomagenesis.
π SIMILAR VOLUMES
melanoma and sarcoma when they reviewed their experience with other malignancies occurring in patients with a diagnosis of sarcoma. 1 Medical Student, Ludwig-Maximilians-Univer- ## METHODS. The authors identified 48 patients with both melanoma and bone or sity, Munich, Germany. soft tissue sarco
The role of elective lymph node dissection (ELND) for treatment of cutaneous melanoma is still debated. Initially, lymphatic mapping technique was performed by an intradermic injection of vital blue dye; subsequently, it was improved by the use of radioguided surgery (RGS). Preliminary experience wi
Several studies report coexistent or subsequent primary tumors (SPT) among patients with malignant melanoma (MM), with the rate of incidence ranging from 1.5-20% depending on the sample size and the length and completeness of follow-up. ## METHODS. The authors followed a cohort of patients with c
The etiology of the autoimmune thyroid, Hashimoto's thyroiditis (HT) is not very clear. However, genetic susceptibility is thought to play a critical role. The vitamin D receptor (VDR)-related endocrine system has been demonstrated to be able to carry out modulation of the immune response. Here, we